NSN 6509-01-493-3405 (6509014933405) Parts Details
Alternative NSN: 6509014933405 |
Item Name: Atipamezole Hydrochloride Inject |
FSG: 65 Medical Dental and Veterinary Equipment and Supplies |
NIIN: 014933405 |
NCB Code: USA (01) |
Manufacturers: Pfizer Inc , Zoetis Inc , Butler Animal Health Supply Llc |
Check out high demanding part numbers ANTISEDAN 5MG ML 10 ML, 6298, 570153.6, 060984, 034363 (Atipamezole Hydrochloride Inject) under NSN 6509-01-493-3405 manufactured by Pfizer Inc, Zoetis Inc, Butler Animal Health Supply Llc. Quote for your desired part numbers.
Part Number's List for NSN 6509-01-493-3405, 6509014933405
-
Part No Manufacturer Item Name QTY RFQ ANTISEDAN 5MG ML 10 ML Pfizer Inc atipamezole hydrochloride inject Avl RFQ 6298 Zoetis Inc atipamezole hydrochloride inject Avl RFQ 570153.6 Pfizer Inc atipamezole hydrochloride inject Avl RFQ 060984 Butler Animal Health Supply Llc atipamezole hydrochloride inject Avl RFQ 034363 Butler Animal Health Supply Llc atipamezole hydrochloride inject Avl RFQ
Characteristics Data of NSN 6509014933405MRC Criteria Characteristic FEAT Special Features SUPPLIED IN 10-ML, MULTIDOSE VIALS CONTAINING 5 MG/ML ATIPAMEZOLE HYDROCHLORIDE STERILE SOLUTION; FOR THE REVERSAL EFFECTS OF MEDETOMIDINE HYDROCHLORIDE, USE INTRAMUSCULAR IN DOGS ONLY; STORE AT CONTROLLED ROOM TEMPERATRUE: 59-86 DEGREES F,AND PROTECT FROM LIGHT; VETERINARY USE ONLY CXCY Part Name Assigned By Controlling Agency ATIPAMEZOLE HYDROCHLORIDE INJECTION 10ML MULTIDOSE VIAL MRC Decoded Requirement Clear Text Reply
MRC | Criteria | Characteristic |
---|---|---|
FEAT | Special Features | SUPPLIED IN 10-ML, MULTIDOSE VIALS CONTAINING 5 MG/ML ATIPAMEZOLE HYDROCHLORIDE STERILE SOLUTION; FOR THE REVERSAL EFFECTS OF MEDETOMIDINE HYDROCHLORIDE, USE INTRAMUSCULAR IN DOGS ONLY; STORE AT CONTROLLED ROOM TEMPERATRUE: 59-86 DEGREES F,AND PROTECT FROM LIGHT; VETERINARY USE ONLY |
CXCY | Part Name Assigned By Controlling Agency | ATIPAMEZOLE HYDROCHLORIDE INJECTION 10ML MULTIDOSE VIAL |
MRC | Decoded Requirement | Clear Text Reply |